EsoBiotec is a Belgian biotechnology company specializing in innovative cancer immunotherapies. Founded in 2020 by Jean-Pierre Latere, the company focuses on engineering immune cells directly within the patient's body to combat cancer and autoimmune diseases. Their proprietary ENaBL (Engineered NanoBody Lentiviral) vector platform enables off-the-shelf, single-injection treatments, aiming to reduce costs and simplify logistics associated with traditional cell therapies. 

In December 2024, EsoBiotec initiated a clinical trial for its lead product, ESO-T01, targeting multiple myeloma, a type of bone marrow cancer. This in-vivo CAR-T cell therapy showed promising early results, achieving cancer-free bone marrow in the first patient without requiring lymphodepletion. 

The company's innovative approach has attracted significant attention, leading to its acquisition by AstraZeneca for up to $1 billion. This strategic move aims to enhance AstraZeneca's cell therapy capabilities, making advanced treatments more accessible to patients worldwide.